No connection

Search Results

GOSS vs NRXS

GOSS
Gossamer Bio, Inc.
BEARISH
Price
$0.37
Market Cap
$87.2M
Sector
Healthcare
AI Confidence
95%
NRXS
NeurAxis, Inc.
BEARISH
Price
$7.45
Market Cap
$85.7M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
GOSS
--
NRXS
--
Forward P/E
GOSS
-2.23
NRXS
-248.33
P/B Ratio
GOSS
-0.71
NRXS
23.35
P/S Ratio
GOSS
1.8
NRXS
24.01
EV/EBITDA
GOSS
-0.94
NRXS
-11.04

Profitability

Gross Margin
GOSS
100.0%
NRXS
84.23%
Operating Margin
GOSS
-333.65%
NRXS
-177.34%
Profit Margin
GOSS
0.0%
NRXS
-218.55%
ROE
GOSS
--
NRXS
-285.36%
ROA
GOSS
-41.86%
NRXS
-80.63%

Growth

Revenue Growth
GOSS
47.1%
NRXS
27.2%
Earnings Growth
GOSS
--
NRXS
--

Financial Health

Debt/Equity
GOSS
--
NRXS
0.13
Current Ratio
GOSS
2.64
NRXS
2.05
Quick Ratio
GOSS
2.36
NRXS
1.85

Dividends

Dividend Yield
GOSS
--
NRXS
--
Payout Ratio
GOSS
0.0%
NRXS
0.0%

AI Verdict

GOSS BEARISH

GOSS exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible fundamental health. The company suffers from negative equity (Price/Book of -0.71) and an unsustainable operating margin of -333.65%. Despite positive revenue growth, the stock is in a catastrophic technical death spiral, losing over 85% of its value in the last six months. The massive discrepancy between the current price ($0.37) and the analyst target ($3.69) suggests a significant lag in analyst updates or extreme speculative optimism not supported by the deterministic data.

Strengths
Strong YoY revenue growth of 47.10%
Healthy short-term liquidity with a Current Ratio of 2.64
Quick Ratio of 2.36 suggests immediate obligations can be met
Risks
Negative Book Value (P/B -0.71) indicating liabilities exceed assets
Piotroski F-Score of 0/9 signals severe fundamental deterioration
Extreme price decay with a 5-year decline of 95.6%
NRXS BEARISH

NRXS exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of financial health metrics. While the stock has seen a speculative 217% price increase over the last year, this is completely disconnected from its fundamentals, as evidenced by a -218.55% profit margin and an extreme Price-to-Book ratio of 23.35. Despite moderate revenue growth and a strong current ratio, the company is destroying equity at an alarming rate (ROE -285.36%). The current valuation is unsustainable without a massive and immediate pivot to profitability.

Strengths
Strong Gross Margin (84.23%) suggesting high product value
Healthy liquidity with a Current Ratio of 2.05
Low Debt/Equity ratio (0.13) reducing immediate insolvency risk
Risks
Extreme operational losses (Profit Margin -218.55%)
Severe fundamental weakness (Piotroski F-Score 1/9)
Extreme valuation premiums (P/S 24.01, P/B 23.35)

Compare Another Pair

GOSS vs NRXS: Head-to-Head Comparison

This page compares Gossamer Bio, Inc. (GOSS) and NeurAxis, Inc. (NRXS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile